LimmaTech Biologics is pioneering the development of innovative vaccines aimed at addressing the pressing issue of antimicrobial resistance. The company utilizes a proprietary self-adjuvanting and multi-antigen vaccine platform, which is designed to enhance the immune response against a range of microbial infections. This platform is complemented by disease-specific vaccine approaches, allowing LimmaTech to create protective solutions that are both effective and transformative in the fight against increasingly untreatable pathogens. With a strong pipeline and decades of expertise, LimmaTech is committed to delivering impactful vaccine candidates that can significantly improve global health outcomes.

Among the key technologies employed by LimmaTech is its bioconjugation technology, which utilizes an in vivo enzyme-based method to create precise linkages between pathogen glycans and immunogenic proteins. This innovative approach streamlines the vaccine development process, making it more cost-effective and safer than traditional chemical conjugation methods. LimmaTech is currently advancing several vaccine candidates through clinical trials, including a tetravalent bioconjugate vaccine targeting the predominant Shigella serotypes and a multivalent toxoid vaccine designed to prevent infections caused by Staphylococcus aureus. These technologies not only enhance the efficacy of the vaccines but also aim to mitigate the risks associated with immune responses, thereby addressing critical needs in the realm of antimicrobial resistance.

Switzerland

LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases.

In addition to our proprietary research, we also develop vaccines together with GSK.

LimmaTech Biologics

Company Details